Suppr超能文献

染色体不稳定性与结直肠癌肝转移切除术后贝伐单抗的预后和疗效相关。

Chromosomal instability is associated with prognosis and efficacy of bevacizumab after resection of colorectal cancer liver metastasis.

机构信息

Department of Colorectal Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, China.

Department of Intensive Care Unit, Sun Yat-Sen University Cancer Center, Guangzhou, China.

出版信息

Ann Med. 2024 Dec;56(1):2396559. doi: 10.1080/07853890.2024.2396559. Epub 2024 Sep 9.

Abstract

INTRODUCTION

Individualized treatment of colorectal cancer liver metastases (CRLM) remains challenging due to differences in the severity of metastatic disease and tumour biology. Exploring specific prognostic risk subgroups is urgently needed. The current study aimed to investigate the prognostic value of chromosomal instability (CIN) in patients with initially resectable CRLM and the predictive value of CIN for the efficacy of bevacizumab.

METHODS

Ninety-one consecutive patients with initially resectable CRLM who underwent curative liver resection from 2006 to 2018 at Sun Yat-sen University Cancer Center were selected for analysis. CIN was evaluated by automated digital imaging systems. Immunohistochemistry (IHC) was performed to detect interleukin-6 (IL-6), vascular endothelial growth factor A (VEGFA) and CD31 expression in paraffin-embedded specimens. Recurrence-free survival (RFS) and overall survival (OS) were analysed using the Kaplan-Meier method and Cox regression models.

RESULTS

Patients with high chromosomal instability (CIN-H) had a worse 3-year RFS rate (HR, 1.953; 95% CI, 1.001-3.810;  = 0.049) and a worse 3-year OS rate (HR, 2.449; 95% CI, 1.150-5.213;  = 0.016) than those with low chromosomal instability (CIN-L). CIN-H was identified as an independent prognostic factor for RFS (HR, 2.569; 95% CI, 1.078-6.121;  = 0.033) and OS (HR, 3.852; 95% CI, 1.173-12.645;  = 0.026) in the multivariate analysis. The protein levels of IL-6, VEGFA and CD31 were upregulated in patients in the CIN-H group compared to those in the CIN-L group in both primary tumour and liver metastases tissues. Among them, 22 patients with recurrent tumours were treated with first-line bevacizumab treatment and based on the clinical response assessment, disease control rates were adversely associated with chromosomal instability ( = 0.043).

CONCLUSIONS

Our study showed that high chromosomal instability is a negative prognostic factor for patients with initially resectable CRLM after liver resection. CIN may have positive correlations with angiogenesis through expression of IL-6-VEGFA axis and be used as a potential predictor of efficacy of bevacizumab.

摘要

简介

由于转移性疾病严重程度和肿瘤生物学的差异,结直肠癌肝转移(CRLM)的个体化治疗仍然具有挑战性。迫切需要探索特定的预后风险亚组。本研究旨在探讨染色体不稳定性(CIN)在最初可切除的 CRLM 患者中的预后价值,以及 CIN 对贝伐单抗疗效的预测价值。

方法

从 2006 年至 2018 年,中山大学肿瘤防治中心对 91 例最初可切除的 CRLM 患者进行了根治性肝切除术,对其进行分析。通过自动化数字成像系统评估 CIN。免疫组织化学(IHC)检测石蜡包埋标本中白细胞介素 6(IL-6)、血管内皮生长因子 A(VEGFA)和 CD31 的表达。使用 Kaplan-Meier 方法和 Cox 回归模型分析无复发生存率(RFS)和总生存率(OS)。

结果

染色体不稳定性高(CIN-H)的患者 3 年 RFS 率(HR,1.953;95%CI,1.001-3.810; = 0.049)和 3 年 OS 率(HR,2.449;95%CI,1.150-5.213; = 0.016)均低于染色体不稳定性低(CIN-L)的患者。CIN-H 是 RFS(HR,2.569;95%CI,1.078-6.121; = 0.033)和 OS(HR,3.852;95%CI,1.173-12.645; = 0.026)的独立预后因素。与 CIN-L 组相比,CIN-H 组的原发性肿瘤和肝转移组织中 IL-6、VEGFA 和 CD31 的蛋白水平上调。其中,22 例复发性肿瘤患者接受了一线贝伐单抗治疗,根据临床反应评估,疾病控制率与染色体不稳定性呈负相关( = 0.043)。

结论

本研究表明,肝切除后,染色体不稳定性高是最初可切除的 CRLM 患者的负预后因素。CIN 可能通过表达 IL-6-VEGFA 轴与血管生成呈正相关,并可作为贝伐单抗疗效的潜在预测因子。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca76/11385633/263db6320f15/IANN_A_2396559_F0001_C.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验